Centre disallows export of Remdesivir injection & API

As India is witnessing a recent surge in COVID-19 cases, there has been a sudden spike in demand for Injection Remdesivir used in the treatment of COVID-19 patients. There is a potential for a further increase in this demand in the coming days. Seven Indian companies are producing Injection Remdesivir under a voluntary licensing agreement with Gilead Sciences, USA. They have an installed capacity of about 38.80 lakh units per month. In light of the above, the Government of India has prohibited the exports of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) till the situation improves. In addition, the government has taken the required steps to ensure easy access of hospital and patients to Remdesivir. All domestic manufactures of Remdesivir have been advised to display on their website, details of their stockists/ distributors to facilitate access to the drug. Drugs inspectors and other officers have been directed to verify stocks and check their malpractices and also take other effective actions to curb hoarding and black marketing. The State Health Secretaries will review this with the Drug Inspectors of the respective States/UTs. The Department of Pharmaceuticals has been in contact with domestic manufacturers to ramp up the production of Remdesivir.